 | Up a level |
Fasching, P. A., Fehm, T., Kellner, S., de Waal, J., Rezal, M., Baler, B., Baake, G., Kolberg, H. -C, Guggenberger, M., Warm, N., Harbeck, N., Wuerstlein, R., Deuker, J. -U, Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W, Breitbach, G. -P, Janni, W., Landthaler, R., Kohls, A., Rezek, D., Nosslet, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Kuemmel, S., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Hadji, P., Wallwiener, D., Grischice, E. -M, Beckmann, M. W. and Brucker, S. Y. (2014). Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd., 74 (12). S. 1137 - 1144. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Hack, C. C., Haeberle, L., Brucker, S. Y., Janni, W., Volz, B., Loehberg, C. R., Hartkopf, A. D., Walter, C-B, Baake, G., Fridman, A., Malter, W., Wuerstlein, R., Harbeck, N., Hoffmann, O., Kuemmel, S., Martin, B., Thomssen, C., Graf, H., Wolf, C., Lux, M. P., Bayer, C. M., Rauh, C., Almstedt, K., Gass, P., Heindl, F., Brodkorb, T., Willer, L., Lindner, C., Kolberg, H-C, Krabisch, P., Weigel, M., Steinfeld-Birg, D., Kohls, A., Brucker, C., Schulz, V, Fischer, G., Pelzer, V, Rack, B., Beckmann, M. W., Fehm, T., Rody, A., Maass, N., Hein, A., Fasching, P. A. and Nabieva, N. (2020). Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast, 50. S. 11 - 19. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080
Nabieva, N., Fehm, T., Haeberle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Popovic, M., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Hack, C. C., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. Eur. J. Cancer, 96. S. 82 - 91. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Nabieva, N., Kellner, S., Fehm, T., Haebrle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann. Oncol., 29 (1). S. 186 - 193. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. -M, Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann. Oncol., 28 (11). S. 2768 - 2773. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2022). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017). Ann. Oncol., 33 (3). S. 355 - 356. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755